CN116419754A - 用于治疗和预防肺部感染的葡萄糖苷酶抑制剂 - Google Patents
用于治疗和预防肺部感染的葡萄糖苷酶抑制剂 Download PDFInfo
- Publication number
- CN116419754A CN116419754A CN202180072511.2A CN202180072511A CN116419754A CN 116419754 A CN116419754 A CN 116419754A CN 202180072511 A CN202180072511 A CN 202180072511A CN 116419754 A CN116419754 A CN 116419754A
- Authority
- CN
- China
- Prior art keywords
- group
- substituted
- alkyl
- optionally substituted
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020903051 | 2020-08-26 | ||
| AU2020903051A AU2020903051A0 (en) | 2020-08-26 | Compounds, compositions and uses thereof | |
| PCT/AU2021/050978 WO2022040741A1 (en) | 2020-08-26 | 2021-08-25 | Glucosidase inhibitors for the treatment and prevention of pulmonary infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116419754A true CN116419754A (zh) | 2023-07-11 |
Family
ID=80352192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180072511.2A Pending CN116419754A (zh) | 2020-08-26 | 2021-08-25 | 用于治疗和预防肺部感染的葡萄糖苷酶抑制剂 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240016786A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4203954A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023540259A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116419754A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021332085B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022040741A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119841765A (zh) * | 2025-01-09 | 2025-04-18 | 中南大学 | Dnj衍生物、药物组合物及其应用 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT202100027464A1 (it) * | 2021-10-26 | 2023-04-26 | Univ Degli Studi Di Camerino | Composizione comprendente iminozuccheri e/o anisodamina per il trattamento di infezioni virali |
| US12569473B2 (en) * | 2022-07-05 | 2026-03-10 | 60 Degrees Pharmaceuticals, Inc. | Methods to treat respiratory infection utilizing castanospermine analogs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017192599A1 (en) * | 2016-05-02 | 2017-11-09 | Florida State University Research Foundation, Inc. | Treatment of zika virus infections using alpha-glucosidase inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1876095A (en) * | 1994-02-25 | 1995-09-11 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
| GB0116643D0 (en) * | 2001-07-09 | 2001-08-29 | Virogen Ltd | Antiviral compounds |
| FR2861991B1 (fr) * | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| WO2011095772A2 (en) * | 2010-02-04 | 2011-08-11 | Summit Corporation Plc | Novel iminosugar therapeutics |
| RS58456B1 (sr) * | 2011-08-01 | 2019-04-30 | Univ Monash | Postupak i formulacije za inhalaciju |
| EP3934688A4 (en) * | 2019-03-08 | 2022-12-21 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR MODULATION OF VIRAL INFECTION THROUGH REGULATION OF GLUCOSYLCERAMIDS |
| EP4106752A4 (en) * | 2020-02-21 | 2024-03-20 | Florida State University Research Foundation, Inc. | TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE-GLYCOPROTEIN PROCESSING INHIBITORS |
| US10980756B1 (en) * | 2020-03-16 | 2021-04-20 | First Wave Bio, Inc. | Methods of treatment |
| CN113425720A (zh) * | 2020-04-03 | 2021-09-24 | 深圳前海诺贝尔奖科学家技术转移转化有限公司 | 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途 |
| US20230270826A1 (en) * | 2020-07-30 | 2023-08-31 | Delta 4 Gmbh | Antiviral use of liraglutide and gefitinib |
-
2021
- 2021-08-25 CN CN202180072511.2A patent/CN116419754A/zh active Pending
- 2021-08-25 AU AU2021332085A patent/AU2021332085B2/en active Active
- 2021-08-25 JP JP2023513877A patent/JP2023540259A/ja active Pending
- 2021-08-25 US US18/022,840 patent/US20240016786A1/en active Pending
- 2021-08-25 WO PCT/AU2021/050978 patent/WO2022040741A1/en not_active Ceased
- 2021-08-25 EP EP21859409.1A patent/EP4203954A4/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017192599A1 (en) * | 2016-05-02 | 2017-11-09 | Florida State University Research Foundation, Inc. | Treatment of zika virus infections using alpha-glucosidase inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| HOLWERDA M等: "Identification of five antiviral compounds from the Pandemic Response Box targeting SARS-CoV-2", BIORXIV, 17 May 2020 (2020-05-17), pages 1, XP055908488, DOI: 10.1101/2020.05.17.100404 * |
| RAJASEKHARAN S.等: "Repurposing of Miglustat to inhibit the coronavirus Severe Acquired Respiratory Syndrome SARS-CoV-2", BIORXIV, 18 May 2020 (2020-05-18), pages 1 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119841765A (zh) * | 2025-01-09 | 2025-04-18 | 中南大学 | Dnj衍生物、药物组合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022040741A1 (en) | 2022-03-03 |
| AU2021332085A1 (en) | 2022-05-19 |
| US20240016786A1 (en) | 2024-01-18 |
| JP2023540259A (ja) | 2023-09-22 |
| AU2021332085B2 (en) | 2022-12-08 |
| EP4203954A4 (en) | 2025-01-01 |
| EP4203954A1 (en) | 2023-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7482250B2 (ja) | 1’-シアノ置換カルバヌクレオシド類似体の吸入製剤 | |
| KR102906597B1 (ko) | 흡입형 닌테다닙 및 닌테다닙 염의 특수 제형 조성물 | |
| JP2024028720A (ja) | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 | |
| JP6021117B2 (ja) | エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用 | |
| TWI564295B (zh) | 3,5-二胺基-6-氯-n-(n-(4-(4-(2-(己基(2,3,4,5,6-五羥基己基)胺基)乙氧基)苯基)丁基)甲脒基)吡-2-甲醯胺 | |
| DK2739268T3 (en) | PROCEDURE AND FORMULATION FOR INHALATION | |
| AU2021332085B2 (en) | Glucosidase inhibitors for the treatment and prevention of pulmonary infections | |
| JP2018172402A (ja) | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 | |
| TW200938232A (en) | Novel dosage and formulation | |
| JP2014525471A (ja) | 咳および咳発作の治療 | |
| JP6919093B2 (ja) | 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも1種の乾燥粉末を含む組成物 | |
| CN117615765A (zh) | 用ALK-5(TGFβR1)抑制剂治疗肺部疾病的方法 | |
| JP2022512208A (ja) | ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法 | |
| US20190282543A1 (en) | Preparation of Respirable Zafirlukast Particles | |
| US20220378727A1 (en) | Dry powder formulations of tamibarotene for pulmonary and intranasal delivery | |
| US20240041805A1 (en) | Pharmaceutical compositions of niclosamide and a protein | |
| HK40096612A (en) | Glucosidase inhibitors for the treatment and prevention of pulmonary infections | |
| CN107205958A (zh) | 包含福莫特罗和布地奈德的药物组合物 | |
| HK40084723B (en) | Inhalation formulations of 1’-cyano substituted carbanucleoside analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40096612 Country of ref document: HK |